Prentice's Approach and the Meta-Analytic Paradigm: A Reflection on the Role of Statistics in the Evaluation of Surrogate Endpoints
DOI10.1111/J.0006-341X.2004.00222.XzbMATH Open1274.62707OpenAlexW2169551309WikidataQ59901721 ScholiaQ59901721MaRDI QIDQ3445296FDOQ3445296
Authors: Ariel Alonso, Geert Molenberghs, Tomasz Burzykowski, Helena Geys, Ziv Shkedy, Fabián S. Tibaldi, José Cortiñas Abrahantes, Marc Buyse, Didier Renard 
Publication date: 11 June 2007
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1111/j.0006-341x.2004.00222.x
Recommendations
- A perspective on surrogate endpoints in controlled clinical trials
- The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials
- The evaluation of surrogate endpoints.
- A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint
- Statistical evaluation of surrogate endpoints with examples from cancer clinical trials
Cites Work
- Criteria for the Validation of Surrogate Endpoints in Randomized Experiments
- Information gain and a general measure of correlation
- Modelling Progression of CD4-Lymphocyte Count and Its Relationship to Survival Time
- Validation of a longitudinally measured surrogate marker for a time-to-event endpoint
- The validation of surrogate endpoints in meta-analyses of randomized experiments
- On meta-analytic assessment of surrogate outcomes
Cited In (13)
- Exploring the Relationship Between Surrogates and Clinical Outcomes: Analysis of Individual Patient Data vs. Meta-regression on Group-Level Summary Statistics
- Learning directed acyclic graphs by determination of candidate causes for discrete variables
- Center-within-trial versus trial-level evaluation of surrogate endpoints
- Statistical Methods for Clinical Studies in the Presence of Surrogate End Points
- Surrogate Marker Evaluation from an Information Theory Perspective
- Quantifying the Effect of the Surrogate Marker by Information Gain
- Proportion of treatment effect mediated by surrogate endpoints
- An information-theoretic approach to surrogate-marker evaluation with failure time endpoints
- A perspective on surrogate endpoints in controlled clinical trials
- Use of the likelihood reduction factor in a path analysis framework to quantify surrogacy in clinical trials
- Statistical evaluation of surrogate endpoints with examples from cancer clinical trials
- Simplified modeling strategies for surrogate validation with multivariate failure-time data
- The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials
This page was built for publication: Prentice's Approach and the Meta-Analytic Paradigm: A Reflection on the Role of Statistics in the Evaluation of Surrogate Endpoints
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3445296)
